Multiple endocrine neoplasia type 1: Genetic and clinical aspects;Néoplasie endocrinienne multiple de type 1 : Aspects génétiques et cliniques

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 4 SUPPL., 2001, Pages

  Calender, Alain ^a   Cadiot, Guillaume ^b   Mignon, Michel ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE;

CONFERENCE PAPER; ENDOCRINE TUMOR; GENE INACTIVATION; GENE MUTATION; GENE STRUCTURE; GENETIC SCREENING; GENETICS; HEREDITY; HUMAN; HYPOPHYSIS TUMOR; LIVER METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PRIMARY HYPERPARATHYROIDISM; PROGNOSIS; RISK FACTOR; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

DUODENAL NEOPLASMS; ENDOCRINE GLAND NEOPLASMS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; PANCREATIC NEOPLASMS;

EID: 0034926789     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (88)

1. Genetic aspects of adenomatosis of endocrine glands
2. The natural history of multiple endocrine neoplasia type Highly uncommon or highly unrecognized?
3. Multiple endocrine neoplasia type 1: Clinical features and management
4. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1
5. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasiá type 1
6. A large multiple endocrine neoplasia type I family with clinical expression suggestive of anticipation
7. Multiple Endocrine Neoplasia type 1 associated with spinal ependymoma
8. Positional cloning of the gene for multiple endocrine neoplasia-type 1
9. Identification of the multiple endocrine neoplasia type 1 gene
10. Clinical studies of multiple endocrine neoplasia type 1
11. Thymic carcinoids in multiple endocrine neoplasia type 1
12. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1
13. Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1
14. Familial multiple endocrine adenoma-peptic ulcer complex
15. Multiple endocrine neoplasia type 1: A 10-year prospective screening study in four kindreds
16. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1
17. Multiple endocrine neoplasia type 1: Clinical and genetic topics
18. Evaluation prospective de la prévalence des tumeurs endocrines duodéno-pancréatiques non fonctionnelles dans la néoplasie endocrine multiple de type 1
19. Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN1
20. Diagnostic des tumeurs neuroendocrines digestives
21. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type 1 multiple endocrine neoplasia
22. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study
23. Histopathology and immunopathology of pancreatic endocrine tumors
24. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia type 1
25. Surgery to cure the Zollinger-Ellison syndrome
26. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN1): Clinical, biochemical, and radiological features of pituitary disease in a large MEN1 kindred
27. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: Clinical features and inheritance pattern
28. Somatotrophinomas in multiple endocrine neoplasia type 1: A review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred
29. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1
30. Adrenal lesion in multiple endocrine neoplasia type 1
31. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): Loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus
32. Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association
33. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1
34. Malignant melanoma in patients with multiple endocrine neoplasia type 1 and the involvement of the MEN1 gene in sporadic melanoma
35. Characterization of the mouse MEN1 gene and its expression during development
36. Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene
37. Primary structure, gene expression and chromosomal mapping of rodents homologs of the MEN1 tumor suppressor gene
38. Characterization of the MEN1 ortholog in Zebrafish
39. Menin, the product of the MEN1 gene, is a nuclear protein
40. Nuclear and cytoplasmic localization of the multiple endocrine neoplasia type 1 gene product, menin
41. Expression analysis of endogenous menin, the product of the multiple endocrine neoplasia type 1 gene, in cell lines and human tissues
42. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
43. Stable overexpression of MEN1 suppresses tumorigeneicity of Ras
44. Germline mutations of the MEN 1 gene in familial multiple endocrine neoplasia type 1 and related states
45. Characterization of mutations in patients with Multiple Endocrine Neoplasia type 1
46. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders
47. Mutation analysis of the MEN1 gene in Multiple Endocrine Neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism
48. A family with isolated hyperparathyroidism segregating a MEN1 missense mutation and showing loss of the wild-type allele in the parathyroid tumors
49. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families
50. Von Hippel-Lindau disease
51. New insights in genetics of digestive neuroendocrine tumors
52. Lethality of multiple endocrine neoplasia type 1
53. Cause of death in multiple endocrine neoplasia type 1
54. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1
55. Interest of the oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome
56. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia type 1
57. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome
58. Glucagonomas: Clinical presentation, diagnosis, and advances in management
59. Calcitonin-secreting tumors of the pancreas: About six cases
60. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1
61. New immunoradioassay for plasma chromogranin A in endocrine tumors
62. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas
63. Imagerie des tumeurs endocrines de la région duodéno-pancréatique
64. Is endoscopic ultrasonography accurate for the localization of pancreatic and duodenal tumors in patients with multiple endocrine neoplasia type 1?
65. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome
66. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy
67. Usefulness of somatostatin receptor scintigraphy in the management of patients with the Zollinger-Ellison syndrome
68. Prospective study of the utility of somatostatin-receptor scintigraphy in the evaluation of patients with multiple endocrine neoplasia type 1
69. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas
70. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: Correlation with primary tumor size
71. Enteropancreatic maligancy associated with multiple endocrine neoplasia type 1
72. Multiple endocrine neoplasm, type 1. Gastrinomas, pancreatic neoplasms, microcarcinoids, the Zollinger-Ellison syndrome, lymph nodes, and hepatic metastases
73. The glucagonoma syndrome. Clinical and pathologic features in 21 patients
74. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area
75. The management of islet cell tumors in patients with multiple endocrine neoplasia type 1 (MEN1)
76. Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1
77. Current perspectives in the surgery of multiple endocrine neoplasias
78. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both
79. Clinical course of nonsurgically treated Zollinger-Ellison syndrome
80. Treatment of gastrinomas with pancreatoduodenectomy
81. Insulinomas associated with multiple endocrine neoplasia type 1: The need for a different surgical approach
82. Surgical aspects of hyperinsulinemic hypoglycemia
83. Intraoperative insulin measurement during surgical management of insulinomas
84. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma
85. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term antisecretory treatment
86. Oesophagite sténosante au coursdu syndrome de Zollinger-Ellison
87. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery
88. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison and multiple endocrine neoplasia type 1. A prospective study